Filgotinib (Glpg0634/Gs-6034), An Oral Selective Jak1 Inhibitor, Is Effective As Monotherapy In Patients With Active Rheumatoid Arthritis: Results From A Randomised, Dose-Finding Study (Darwin 2)

Objectives To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX).Methods In this 24-week phase IIb study, patients with moderately to severely active RA were randomised (1: 1: 1: 1) to receive 50, 100 or 200 mg filgotinib once daily, or placebo, after a >= 4-week washout from MTX. The primary end point was the percentage of patients achieving an American College of Rheumatology (ACR) 20 response at week 12.Results Overall, 283 patients were randomised and treated. At week 12, significantly more patients receiving filgotinib at any dose achieved ACR20 responses versus placebo (>= 65% vs 29%, p<0.001). For other key end points at week 12 (ACR50, ACR70, ACR-N, Disease Activity Score based on 28 joints and C reactive protein, Clinical Disease Activity Index, Simplified Disease Activity Index and Health Assessment Questionnaire-Disability Index) significant differences from baseline in favour of filgotinib 100 and 200 mg versus placebo were seen; responses were maintained or improved through week 24. Rapid onset of action was observed for most efficacy end points. Dose-dependent increases in haemoglobin were observed. The percentage of patients with treatment-emergent adverse events (TEAE) was similar in the placebo and filgotinib groups (similar to 40%). Eight patients on filgotinib and one on placebo had a serious TEAE, and four patients, all of whom received filgotinib, experienced a serious infection. No tuberculosis or opportunistic infections were reported.Conclusions Over 24 weeks, filgotinib as monotherapy was efficacious in treating the signs and symptoms of active RA, with a rapid onset of action. Filgotinib was generally well tolerated.